semaj83/ctmatch_classification huggingface dataset:
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Bronchial Asthma Males or females age 18 or greater and 65 or less The diagnosis of asthma confirmed by at least one of the following as assessed at least once during the past 5 years before the study Reversibility to β2-agonists ≥12% predicted and ≥200ml after 400μg inhaled salbutamol or equivalent Bronchial hyper-responsiveness to methacholine or histamine Peak-flow variability of >20% over a period of 14 days Fall in FEV1 >12% and >200ml when tapering treatment (ICS, oral steroid, LABA and/or LTRA) Subject is taking regular maintenance medication (GINA step 4-5) for past 6 months that includes Inhaled corticosteroid at a dosage ≥500μg fluticasone equivalent per day AND Long acting ß2-agonist at a dosage of ≥100μg per day salmeterol dose aerosol or equivalent) Per protocol bronchial hyper-responsiveness to methacholine (PC20<4 mg/ml)  Asthma exacerbation during the prior 4 weeks Subject has 5 or more hospitalizations for exacerbations of asthma in the previous year or 1 or more ICU admission for mechanical or endotracheal intubation for asthma in the previous year Respiratory tract infection within past 4 weeks Subject has a known sensitivity to medications required to perform bronchoscopy Subject is using immunosuppressant therapy other than oral steroid therapy Subject is on anticoagulant medication including anti-platelet agents Subject has bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 125,000/mm2 or known coagulopathy (INR >1.5) Subject has other respiratory diseases including interstitial lung disease, emphysema, cystic fibrosis, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (total IgE of >1000 Units/mL with positive specific IgE to aspergillus and evidence of central bronchiectasis) Subject has segmental atelectasis, lobar consolidation, significant or unstable pulmonary infiltrate, or pneumothorax, confirmed on x-ray. Bronchiectasis on HR-CT-of the chest, both centrally or peripherally will be excluded Subject has clinically significant cardiovascular disease, including myocardial infarction, angina, cardiac dysrhythmia, conduction defect, cardiomyopathy, aortic aneurysm, or stroke at the discretion of the investigator
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Melanoma Brain Metastases Cohort 1 and 3 ≥18 years of age Written informed consent AJCC Stage IV (any T, any N, M1c) histologically confirmed melanoma or unknown primary melanoma. Patients must have at least 1 radiological definitive brain metastasis that is ≥ 5mm and ≤40mm measurable per version 1.1 guidelines In patients with prior BRAF inhibitor treatment, intracranial disease progression must be demonstrated (RECIST >20% or new measurable brain metastases) compared with nadir of intracranial response during BRAF inhibitor treatment, and confirmed with a second MRI brain scan after drug washout period (+/‐ 3 days) No prior localised treatment for brain metastases (eg. surgery or radiotherapy) Neurologically asymptomatic from brain metastases Eastern Cooperative Oncology Group (ECOG) Performance Status of 0‐2, and life expectancy > 30 days Able to undergo MRI with Gadolinium contrast agent Adequate haematological, hepatic and renal organ function  Any melanoma brain metastasis >40mm Ocular melanoma Prior treatment with an anti‐PD‐1 or anti‐PD‐L1 , anti‐PD‐L2, anti‐CD137, or anti‐CTLA‐4 antibody, or any other antibody or drug specifically targeting T‐cell co‐stimulation or checkpoint pathways Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll Current systemic treatment with corticosteroids, except prednisone at nonimmunosuppressive doses of ≤ 10 mg/day (or equivalent). Past treatment for non‐neurological symptoms allowed, if ceased 2 weeks prior to starting study treatment. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient on a stable dose. Non‐absorbed intraarticular steroid injections will be permitted Any investigational drug or other systemic drug therapy for melanoma within 28 days or 5 half‐lives from baseline Known to be HIV positive, or a positive test for hepatitis B and C  Another malignancy or concurrent malignancy unless disease‐free for 3 years Serious or unstable pre‐existing medical conditions or other conditions that could interfere with the patient's safety, consent, or compliance Pregnant or breastfeeding females
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Melanoma Cutaneous melanoma with a tumour thickness of at least 1,00mm Positive sentinel node with micro metastases of max. 2mm in diameter  Mucosal or ocular melanoma Cutaneous melanoma located in the head/neck region Evidence of satellite, in transit or local metastases / recurrences Macro metastases of the SN or micro metastases of >2mm in diameter Additional immune-suppressive therapy Pregnant of lactating women
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Rectal Neoplasms Patients with biopsy-proven confirmed rectal cancer MRI stage: T3/T4 and/or N1/N0 No contraindication to MRI and PET-CT  Contraindication to MRI and/or PET-CT Inability to consent Severe claustrophobia Distant metastases Synchronous tumour
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Frontal Lobe Epilepsies (Patients) Age between 18 and 50 Diagnosis of frontal lobe epilepsy Written consent to participate Right-handed Hospital Anxiety and Depression Scale Score under 10 Obsessive Compulsive Inventory Score under 40 Sufficient language skills Social insurance (controls)  (Patients) Seizures types other than epileptic (psychogenic etc.) Mental retardation Epilepsies other than FLE Other known neurological diseases Hospital Anxiety and Depression Scale Score over 10 Obsessive Compulsive Inventory Score over 40 Pregnancy non-MRI suitable transplants (cardiac pacemaker etc.), claustrophobia, orthopedic diseases that prevent lying in the scanner During period of other studies
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Lung Cancer COPD Subjects must meet all of the following Be enrolled in COPDGene® Phase 1 with or without enrollment in Phase 2 with newly diagnosed, (within the time of enrollment), non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) Documented GOLD stage 1-4 COPD or a history of smoking with no COPD Signed HIPAA Research Authorization and a Release of Protected Health Information form to collect and review medical records regarding lung cancer diagnosis, treatment, and outcome
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 55.0-74.0,  Lung Carcinoma Solitary Pulmonary Nodule Cigarette Smoker Patients at high risk for lung cancer as defined by the United States Preventive Services Task Force (USPSTF) for lung cancer screening, with a newly discovered indeterminate pulmonary nodules (IPN) (7-30 mm diameter) on CT (newly seen on medical imaging, without prior examinations to demonstrate that the lesion has been stable for two or more years), untreated The patient is aged 55 to 74 years of age, AND Has a 30 or more pack-year history of smoking, AND Currently smokes, or, if the patient has quit smoking, has quit within the last 15 years, or An adult patient with a newly diagnosed, untreated primary lung cancer, with a minimum diameter of 7 mm The patient must be able to give informed consent, which will a layman's explanation of the estimated amount of additional radiation that the patient will receive from the investigational PET/CT scan using 18F-FSPG  Pregnant or lactating patients will be excluded, as will females of childbearing potential who refuse to undergo a serum or urinary beta-human chorionic gonadotropin (HCG) pregnancy test the day of either the 18F-FSPG or the 18F-FDG PET/CT scans Patients with a body weight of 400 pounds or more or a body habitus or disability that will not permit the imaging protocol to be performed The patient's inability to lie still for the entire imaging time (such as due to cough, severe arthritis), as assessed upon pre-enrollment screening, will not be enrolled A recognized active lung infection Previous systemic or radiation treatment for cancer of any type within 2 years Refusal to undergo a clinically indicated biopsy or a 24-month period of follow-up, if needed, to resolve the etiology of their IPN (benign versus cancer) Non-oncologic co-morbidities suggesting a life span of less than two years if not treated, as determined by the potential subjects' treating physician
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Pulmonary nodule on a recent CT non-visible on standard-size bronchoscopy  missing informed consent
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Lung Diseases, Interstitial Lung Cancer equal to above 40 years old
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rectal Neoplasms Adenocarcinoma of the rectum classified clinically T2, T3a, T3b (penetration in the mesorectal fat between 1 to 5 mm) by TNM classification (Tumour Node Metastase), < 5 cm largest diameter, < half rectal circumference (by MRI staging), N0-N1 (any node < 8 mm diameter on MRI), M0 Operable patient Tumour accessible to endocavitary contact X-Ray Brachytherapy with a distance from the lower tumour border to the anal verge ≤ 10cm 18 years or above No comorbidity preventing treatment Adequate birth control Patient having read the information note and having signed the informed consent Health care insurance available Follow-up possible  Inoperable patient T1, T3cd, T4, T≥ 5cm, T≥ ½ circumference Patient N2 at diagnosis or N1 with any node > 8 mm diameter Patient presenting metastasis at diagnosis Previous pelvic irradiation Tumour with extramural vascular invasion Simultaneous progressive cancer Tumour invading external anal sphincter and within 1 mm, and the levator muscle Patient unable to receive CXB or CRT Tumour with poor differentiation (G3)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 55.0-75.0,  Lung Cancer relatives of the lung cancer patients age older than 55 years old or age older than the age of onset of lung cancer proband if the family members were less than 55 years old compulsory signing the consent agreement after understanding the purpose of study and the exposure of radiation  proved lung cancer either with or without treatment presence of hemoptysis or history of remarkable lung fibrosis any other cancer history or chest CT examination within one year
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostatic Neoplasms Able to provide informed consent ECOG performance status 0-1 Histologic confirmation of prostate adenocarcinoma Stage IV disease, with up to 5 metastatic tumours outside of the prostate and pelvic lymph nodes ≤ 3 tumours within any given organ system (e.g. up to 3 brain metastases, or 3 liver metastases) All sites of disease are amenable to stereotactic radiotherapy  Castrate resistant prostate cancer Evidence of spinal cord compression Previous radiotherapy for current cancer (with the exception of upfront management of the primary prostate tumour, brain metastasis(es) prior to androgen deprivation therapy) Inability to safely treat all sites of visible disease Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Solitary Pulmonary Nodule Coin Lesion, Pulmonary Lung Neoplasms Carcinoma, Non-small-cell Lung The target population includes adults with small lung nodules that may represent a new diagnosis of lung cancer, who typically would be managed by CT surveillance in usual clinical practice. Thus, we will enroll all adult patients aged ≥21 years at least one nodule measuring ≤15 mm in widest axial diameter on chest CT  Pregnant Women Children Known diagnosis of cancer (except non-melanoma skin cancer) within 5 years Multiple (>10) nodules on chest CT scan
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 45.0-74.0,  Cardiovascular Diseases Heart Diseases Atherosclerosis Asthma Carotid Artery Diseases Coronary Disease Hypercholesterolemia Hypertension Diabetes Mellitus Obesity
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atherosclerosis Coronary Disease Arterial Occlusive Diseases Peripheral Vascular Diseases Cardiovascular Diseases
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiovascular Diseases Peripheral Vascular Diseases Atherosclerosis Cerebrovascular Disorders Myocardial Infarction Heart Diseases Hyperhomocysteinemia
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Intermittent Claudication Group I (n=25 PAD patients). This sample will represent the population of veterans with PAD with mild mobility impairment secondary to intermittent claudication in the gastrocsoleus muscles for PAD Subjects diagnosis of PAD (acute or chronic occlusive arterial disease), with or without diabetes mellitus positive Edinburgh Claudication Questionnaire Fontaine stage IIa only (mild claudication, walking distance > 200 feet (one-half block) ambulatory, without assistive devices calf muscle claudication within 10 minutes of treadmill walking and calf muscle exercise Group II (n=25 normal control/reference subjects). This reference sample will represent the population of adults without PAD and related problems. They will undergo the PET-exercise testing for perfusion and glucose metabolism measurements, but will not perform the exercise training intervention for Controls healthy adults, matched by age and sex to PAD subjects  for PAD and Control Subjects PAD secondary to Buerger's disease, autoimmune arteritis, fibromuscular dysplasia, chronic and repetitive occupational trauma, venous stasis, hypercoagulability disorder, or arterial embolic disease inability to perform ankle dorsi and plantar flexion exercise cigarette smoking within last 6 months severe claudication, leg rest pain, skin ulceration, necrosis or gangrene (Fontaine stage >= IIa) poorly controlled diabetes mellitus (bA1c >= 9%) poorly controlled hypertension (resting BP > 140/90 mmHg) Raynaud's syndrome changes in prescribed cardiovascular medications within the past 6 months exertional angina, dyspnea, fatigue, or dizziness
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Hypertension Postmenopausal women Mild to moderate hypertension Statin therapy or LDL≤ 4.1 mmol/L  Severe hypertension LDL > 4.1 mmol/L if not taking anti-hyperlipidemic medication Certain hormonal therapy History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease Diabetes Raynaud's disease or any other significant peripheral vascular disease Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/
Patient description: A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Peripheral Vascular Diseases Receive stable peritoneal dialysis patients for more than 3 months  Active infection, malignancy and recent hospitalization